US 12,391,689

Application 17/689,741 · Granted Aug 19, 2025

Synthesis of key intermediate of kras g12c inhibitor compound

Estimated expiration

February 1, 2040

13y 75d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Nov 15, 2019
+ 20 years
Nov 15, 2039
PTA +593d
Jun 30, 2041
TD cap (US 11,299,491)
Feb 1, 2040
Final
Feb 1, 2040

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
March 8, 2022
Earliest effective filing
November 15, 2019
Issue date
August 19, 2025
PTA
+593 days
Base expiry (before PTA)
November 15, 2039

November 15, 2019 + 20 years = November 15, 2039 + 593 PTA days = June 30, 2041

  • Continuation of application 16/685,841, filed Nov 15, 2019, issued as US 11,299,491
  • PRO62/768,802 — Provisional — not used for base term
  • PRO62/768,802 — Provisional — not used for base term

Terminal disclaimers

TD approved1 approved, 1 filed

TD caps expiration to February 1, 2040 (earliest expiring referenced patent: US 11,299,491)

  • US 11,299,491· Application 16/685,841Capping patent

    Synthesis of key intermediate of kras g12c inhibitor compound

    Filing date
    Nov 15, 2019
    Earliest effective filing
    Nov 15, 2019
    Issue date
    Apr 12, 2022
    PTA
    +78 days
    Calculated expiration
    Feb 1, 2040

    Nov 15, 2019 + 20y + 78d PTA = Feb 1, 2040

  • US 12,391,689· Application 17/689,741(from application 17/689,741)

    Synthesis of key intermediate of kras g12c inhibitor compound

    Filing date
    Mar 8, 2022
    Earliest effective filing
    Nov 15, 2019
    Issue date
    Aug 19, 2025
    PTA
    +593 days
    Calculated expiration
    Jun 30, 2041

    Continuation of 16/685,841, filed Nov 15, 2019, issued as US 11,299,491

    Nov 15, 2019 + 20y + 593d PTA = Jun 30, 2041

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/689,741 · US 12,391,689

PatentReply compiles the prosecution history behind US 12,391,689: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12391689

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.